Our Stroke portfolio delivers life-saving interventional solutions for patients with ischemic stroke for the best chance of a full recovery.
Our Vascular portfolio is transforming thrombectomy care for people suffering from devastating vascular diseases, including venous thromboembolism and acute limb ischemia.
We are developing the Telos robotic platform* to expand access to lifesaving care through purposeful design and innovation.
*Currently in development. Not approved for use or available for sale.
Imperative Care is addressing gaps across the entire patient journey to elevate care for patients suffering from stroke and other devastating vascular diseases.
Back to News
June 18, 2026
Latest Analysis of Imperative Care’s SYMPHONY-PE Trial Suggests Early Thrombectomy May Improve Key Measures of Heart Recovery in Intermediate-Risk Pulmonary Embolism
September 17, 2025
Imperative Care Announces Late-Breaking Data Presentation and Peer-Reviewed Publication from Pivotal Trial of Symphony Thrombectomy System in Patients with Acute Pulmonary Embolism
May 13, 2025
Imperative Care Announces Completion of Enrollment in the SYMPHONY-PE IDE Study for Treatment of Pulmonary Embolism
March 24, 2025
Imperative Care Expands Symphony Precision Thrombectomy Portfolio with Purpose-Built Design for the Treatment of Venous Thrombosis
July 8, 2024
Statement on Intellectual Property Litigation
January 29, 2024
Imperative Care Announces Four Senior Leadership Appointments
August 10, 2023
Imperative Care Unveils New Structure to Elevate Care for Patients with Vascular Diseases
April 11, 2022
TRUVIC Announces 510(k) Clearance for the Prodigy™ Thrombectomy System
Media Contact
Rigo Magana
Corporate Communications
rmagana@imperativecare.com
Investor Contact
Phil Nalbone
VP of Corporate Development and Investor Relations
pnalbone@imperativecare.com
Contact us
